56496-90-3

Upstream product

• 66933-01-5 4-(2,6-dihydroxy-4-[1',1'-dimethylheptyl]phenyl)-6,6-dimethylbicyclo[3.1.1]heptan-2-one 
• 61597-37-3 4-(1-hydroxy-1-methylethyl)-1-methoxy-1,4-cyclohexadiene 
• 56469-10-4 5-(1',1'-dimethyl-n-heptyl)-1,3-dihydroxybenzene 
• 109-63-7 trifluoroborane diethyl ether 
• 70308-99-5 1-isobutoxy-4-(1-hydroxy-1-methylethyl)-1,4-cyclohexadiene 
• 56469-13-7 3-(1',1'-dimethylheptyl)-7,8-dihydro-1-hydroxyspiro[9H-dibenzo-[ b,d]pyran-9,2'-[ 1,3]-dioxolan]-6(10H)-one 

Relevant academic research and scientific papers

Synthesis and pharmacology of 11-nor-1-methoxy-9- hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: New selective ligands for the cannabinoid CB2 receptor

Fourteen novel CB2 receptor selective cannabinoids were synthesized via initial Lewis acid catalyzed rearrangement of resorcinol precursors to obtain the cannabinoid moiety. These are the 1-methoxy-9- hydroxyhexahydrocannabinols and the 1-deoxy

Novel polymorphic crystalline form of dibenzopyranone

Stable polymorphic crystalline form of trans-dl-1-hydroxy-3-(1',1'-dimethylheptyl)-6,6-dimethyl-6,6a,7,8,-10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one, capable of producing significant blood levels in mammals for long periods of time after oral administration of the drug.

Process for preparing dl-cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones

Reaction of a 5-substituted resorcinol with a 1-alkoxy-4-(1-hydroxy-1-methylethyl)-1,4-cyclohexadiene in the presence of a suitable catalyst affords the corresponding dl-cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one.

2,6-Methano-2H-1-benzoxocins

Novel 2-oxy-5-isopropylidene-7-hydroxy-9-substituted-2,6-methano-3,4,5,6-tetrahydro-2H-1-benzoxocins are prepared by condensing a 5-(substituted)resorcinol with a 1-alkoxy-4-(1-hydroxy-1-methylethyl)-1,4-cyclohexadiene in the presence of a suitable catalyst. The new benzoxocin derivatives are useful in the synthesis of certain dibenzo[b,d]pyran-9-ones, valuable as anti-anxiety, analgesic, and anti-depressant drugs.

Preparation of cis-hexahydrodibenzopyranones

Reaction of 4-(1-hydroxy-1-methylethyl)-3-cyclohexen-1-one with a 5-substituted resorcinol in the presence of boron tribromide, boron trifluoride or stannic chloride provides, depending upon the duration of reaction, either a 2,7-dihydroxy-5-isopropyliden

Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs

Use of 1-hydroxy-3-alkyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones as antiemetic drugs.

Hexahydro-dibenzo[b,d]pyran-9-ones as anticonvulsant drugs

Use of 1-hydroxy-3-alkyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones as anticonvulsant drugs.

Hexahydro-dibenzo[b,d]pyran-9-ones in treatment of glaucoma

Use of 1-hydroxy-3-alkyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones in treatment of glaucoma.

Preparation of cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones and intermediates therefor

Reaction of a 5-substituted resorcinol with a ketal of 4-(1-hydroxy-1-methylethyl)-3-cyclohexen-1-one in the presence of a suitable catalyst effects condensation to provide substantially exclusively a cis-1-hydroxy-3-substituted-6-6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one.

Process for converting cis-hexahydrodibenzo[b,d]pyran-9-ones to trans-hexahydrodibenzo[b,d]-pyran-9-ones

Reaction of cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones with an aluminum halide in an unreactive organic solvent effects complete epimerization to provide the corresponding trans-1-hydroxy-3-substituted-6